Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31

Abstract

We developed a gene expression-based predictive model for degree of benefit from trastuzumab and demonstrated that HER2-negative tumors belong to the moderate benefit group, thus providing justification for testing trastuzumab in HER2-negative patients (NSABP B-47).